<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="UPDATE? Clinical trials with the neuraminidase inhibitors (NIs) oseltamivir and" exact="zanamivir" post="and and meta-analyses of oseltamivir therapy administered within 36"/>
 <result pre="was shown to reduce symptoms by 3.6 days (5). Inhaled" exact="zanamivir" post="shortened the duration of major influenza symptoms by 3"/>
 <result pre="placebo in individuals who were febrile at enrollment and received" exact="zanamivir" post="within 30 h (3). In low-risk outpatients, NI treatment"/>
 <result pre="ventilated patients, oseltamivir should be administered by nasogastric tube. If" exact="zanamivir" post="is required in a severely ill patient, intravenous zanamivir"/>
 <result pre="If zanamivir is required in a severely ill patient, intravenous" exact="zanamivir" post="is recommended at a dose of 600 mg every"/>
 <result pre="a dose of 600 mg every 12 h. If intravenous" exact="zanamivir" post="is needed, it can be obtained by request to"/>
 <result pre="(0830-1630 weekdays), 613-941-3061 (after hours and weekends), fax 613-941-3194). Inhaled" exact="zanamivir" post="is not advised in a severely ill patient because"/>
 <result pre="because the inhaled powder deposits chiefly in the upper airways." exact="Zanamivir" post="powder administered through ventilator circuits is contraindicated. The recommended"/>
 <result pre="resistance. Suspected oseltamivir resistance should prompt a switch to intravenous" exact="zanamivir" post="until results of antiviral susceptibility testing are available. Repeated"/>
 <result pre="be reduced by early institution of post-exposure prophylactic oseltamivir or" exact="zanamivir" post="(16). Hospitalized patients and HCW, regardless of their vaccine"/>
 <result pre="oseltamivir at a dose of 75 mg once daily or" exact="zanamivir" post="inhalation, two puffs (10 mg) once daily for seven"/>
 <result pre="antiviral prophylaxis. Pre-exposure prophylaxis Pre-exposure prophylaxis with either oseltamivir or" exact="zanamivir" post="for hospitalized patients or staff is not routinely recommended."/>
 <result pre="Trialists) Study GroupRandomised trial of efficacy and safety of inhaled" exact="zanamivir" post="in treatment of influenza A and B virus infectionsLancet19983521877819863784"/>
 <result pre="virus infectionsLancet19983521877819863784 3.HaydenFGOsterhausADMETreanorJJet al.Efficacy and safety of the neuraminidase inhibitor" exact="zanamivir" post="in the treatment of influenzaviris infectionsNew Engl J Med1997337874809302301"/>
 <result pre="and pathogenicity: Observation-based trialsAm J Epidemiol20071652122117088311 TABLE 1 Oseltamivir and" exact="zanamivir" post="treatment of influenza Updated from: The use of antiviral"/>
 <result pre="using a proprietary &quot;Diskhaler&quot; device distributed together with the medication." exact="Zanamivir" post="is a dry powder, not an aerosol, and should"/>
 <result pre="other devices typically used for administering medications in aerosolized solutions." exact="Zanamivir" post="is not recommended for persons with chronic respiratory diseases"/>
</results>
